LA
AMLX icon

Legacy Advisors’s Amylyx Pharmaceuticals AMLX Stock Holding History

Legacy Advisors’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-50,000
Closed -$162K – 412
2024
Q3 		$162K Hold
50,000
– – 0.02% 365
2024
Q2 		$95K Hold
50,000
– – 0.01% 323
2024
Q1 		$142K Hold
50,000
– – 0.02% 306
2023
Q4 		$736K Hold
50,000
– – 0.09% 164
2023
Q3 		$916K Buy
+50,000
New +$1.06M 0.15% 131

Other funds holding AMLX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Legacy Advisors's AMLX Position: Q4 2024 in Review

Legacy Advisors sold out of Amylyx Pharmaceuticals (AMLX) in Q4 2024, closing a stake of 50,000 shares — an estimated $162K sold.

Legacy Advisors first reported a position in AMLX in Q3 2023 and held it in 5 quarters. The position peaked at $916K in Q3 2023. 122 funds tracked by Wall St. Rank hold AMLX as of Q4 2024.

  • Legacy Advisors reported no remaining Amylyx Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Legacy Advisors sold 50,000 Amylyx Pharmaceuticals shares in Q4 2024, an estimated $162K.
  • Legacy Advisors first reported a position in Amylyx Pharmaceuticals in Q3 2023 and held it in 5 quarters.
  • Legacy Advisors's Amylyx Pharmaceuticals position peaked at $916K in Q3 2023.
  • 122 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q4 2024.

Based on Legacy Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.